NCT07111988

Valbenazine in Obsessive Compulsive Disorder

Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).

Detailed description

The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD). Subjects will either receive double-blind valbenazine or inactive placebo for 6 weeks. This will be followed by a 2-week washout period and then 6 weeks of being assigned to the other agent (valbenazine or placebo). The hypothesis to be tested is that valbenazine will significantly improve symptoms of OCD compared to placebo.

Conditions

• Obsessive-Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Valbenazine	Selective vesicular monoamine transporter 2 (VMAT2) inhibitor
DRUG	Placebo	Pill that contains no medicine

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-08-08
• Last updated: 2026-02-05

Regulatory

• FDA-regulated drug study